Arcellx Inc. (ACLX) is a clinical-stage biopharmaceutical company that specializes in the development of adaptive and controllable cell therapies for the treatment of cancer and other serious diseases. The company's proprietary platform is based on the use of controllable and switchable CAR-T cells, which can be activated or deactivated using small molecules. This approach is designed to improve the safety and efficacy of CAR-T cell therapies, as well as enable physicians to better manage patients' treatment.
Arcellx's lead product candidate, ARC-8, is a controllable CAR-T cell therapy being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The company is also developing a pipeline of other controllable CAR-T cell therapies for the treatment of multiple myeloma, solid tumors, and other hematological malignancies.
Arcellx was founded in 2015 and is headquartered in Gaithersburg, Maryland. The company completed its initial public offering (IPO) in August 2021, raising $174 million.
Arcellx Inc. (ACLX) is a clinical-stage biopharmaceutical company that specializes in the development of adaptive and controllable cell therapies for the treatment of cancer and other serious diseases. The company's proprietary platform is based on the use of controllable and switchable CAR-T cells, which can be activated or deactivated using small molecules. This approach is designed to improve the safety and efficacy of CAR-T cell therapies, as well as enable physicians to better manage patients' treatment.